A randomized double-blind, placebo-controlled trial of ganaxolone in children and adolescents with fragile X syndrome
Published 2017 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
A randomized double-blind, placebo-controlled trial of ganaxolone in children and adolescents with fragile X syndrome
Authors
Keywords
Fragile X syndrome, Ganaxolone, Clinical trial, Children, Adolescents
Journal
Journal of Neurodevelopmental Disorders
Volume 9, Issue 1, Pages -
Publisher
Springer Nature
Online
2017-06-10
DOI
10.1186/s11689-017-9207-8
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Mavoglurant in fragile X syndrome: Results of two randomized, double-blind, placebo-controlled trials
- (2016) Elizabeth Berry-Kravis et al. Science Translational Medicine
- The GABAAreceptor is an FMRP target with therapeutic potential in fragile X syndrome
- (2015) Sien Braat et al. CELL CYCLE
- The GABAA Receptor as a Therapeutic Target for Neurodevelopmental Disorders
- (2015) Sien Braat et al. NEURON
- Insights into GABAAergic system deficits in fragile X syndrome lead to clinical trials
- (2015) Sien Braat et al. NEUROPHARMACOLOGY
- Therapeutic Strategies in Fragile X Syndrome: From Bench to Bedside and Back
- (2015) Christina Gross et al. Neurotherapeutics
- Evaluation of the neuroactive steroid ganaxolone on social and repetitive behaviors in the BTBR mouse model of autism
- (2015) Tatiana M. Kazdoba et al. PSYCHOPHARMACOLOGY
- Effect of Speaker Gaze on Word Learning in Fragile X Syndrome: A Comparison With Nonsyndromic Autism Spectrum Disorder
- (2015) David P. Benjamin et al. JOURNAL OF SPEECH LANGUAGE AND HEARING RESEARCH
- Positron Emission Tomography (PET) Quantification of GABAA Receptors in the Brain of Fragile X Patients
- (2015) Charlotte D’Hulst et al. PLoS One
- Fragile X syndrome neurobiology translates into rational therapy
- (2014) Sien Braat et al. DRUG DISCOVERY TODAY
- Longitudinal Profiles of Adaptive Behavior in Fragile X Syndrome
- (2014) C. Klaiman et al. PEDIATRICS
- Neurosteroid interactions with synaptic and extrasynaptic GABAA receptors: regulation of subunit plasticity, phasic and tonic inhibition, and neuronal network excitability
- (2013) Chase Matthew Carver et al. PSYCHOPHARMACOLOGY
- The FMRP regulon: from targets to disease convergence
- (2013) Esperanza Fernández et al. Frontiers in Neuroscience
- Pharmacological treatment of fragile X syndrome with GABAergic drugs in a knockout mouse model
- (2012) Inge Heulens et al. BEHAVIOURAL BRAIN RESEARCH
- FMR1 CGG allele size and prevalence ascertained through newborn screening in the United States
- (2012) Flora Tassone et al. Genome Medicine
- The GABAA Receptor Agonist THIP Ameliorates Specific Behavioral Deficits in the Mouse Model of Fragile X Syndrome
- (2011) Jose Luis Olmos-Serrano et al. DEVELOPMENTAL NEUROSCIENCE
- Epigenetic Modification of the FMR1 Gene in Fragile X Syndrome Is Associated with Differential Response to the mGluR5 Antagonist AFQ056
- (2011) S. Jacquemont et al. Science Translational Medicine
- Reduced GABA A receptors and benzodiazepine binding sites in the posterior cingulate cortex and fusiform gyrus in autism
- (2010) Adrian L. Oblak et al. BRAIN RESEARCH
- Defective GABAergic Neurotransmission and Pharmacological Rescue of Neuronal Hyperexcitability in the Amygdala in a Mouse Model of Fragile X Syndrome
- (2010) J. L. Olmos-Serrano et al. JOURNAL OF NEUROSCIENCE
- Fragile X syndrome: from molecular genetics to therapy
- (2009) C D'Hulst et al. JOURNAL OF MEDICAL GENETICS
- Expression of the GABAergic system in animal models for fragile X syndrome and fragile X associated tremor/ataxia syndrome (FXTAS)
- (2008) Charlotte D'Hulst et al. BRAIN RESEARCH
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started